Status:
COMPLETED
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
Lead Sponsor:
AstraZeneca
Conditions:
Psychosis
Eligibility:
All Genders
15-25 years
Phase:
PHASE3
Brief Summary
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first...
Eligibility Criteria
Inclusion
- Patients experiencing their first psychotic episode
- Male or Female
- Aged 15-25
Exclusion
- Previous treatment with antipsychotic medication (longer than 1 week)
- History of a clinically significant physical illness
- Organic disorder presenting with psychotic symptoms
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00449397
Start Date
July 1 2003
End Date
January 1 2006
Last Update
January 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Sites
Melbourne, Australia